TRPM7

Across TCGA pan-cancer cohorts, TRPM7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRPM7 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRPM7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRPM7 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, LSCC, and GBM are the cancer types where TRPM7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.623	1.000	.040	10	view →
LSCC	DFS	Median	All	0.968	0.902	.029	5	view →
GBM	DFS	Quartile	All	0.229	0.444	.019	2	view →
CCRCC	DFS	Quartile	III,IV	0.310	0.649	.041	2	view →
LUAD	OS	Quartile	All	0.940	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRPM7–HNSC (DFS)

Open the HNSC breakdown →